2-Phenylbenzothiazoles featuring heteroaryl sulfonamide end-capping substructures as developable mPGES-1 inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Microsomal prostaglandin E2 (PGE2) synthase-1 (mPGES-1) is a key target for anti-inflammatory drugs.
• Inhibiting mPGES-1 offers a therapeutic strategy for inflammatory conditions.

Purpose of the Study:

• To design and synthesize novel 2-phenylbenzothiazole derivatives as mPGES-1 inhibitors.
• To evaluate the inhibitory potential and selectivity of these compounds against mPGES-1.

Main Methods:

• Synthesis of 2-phenylbenzothiazole derivatives with heteroaryl sulfonamide end-capping.
• Cell-free assay to measure PGE2 formation and determine IC50 values.
• Selectivity profiling against cyclooxygenase (COX)-1, COX-2, 5-lipoxygenase (5-LOX), and FLAP.

Main Results:

• Several novel derivatives demonstrated potent inhibition of human mPGES-1, with IC50 values ranging from 0.72-3.40 µM.
• Compound 21, featuring a quinoxalinedione moiety, exhibited the strongest inhibition (IC50 = 0.72 µM).
• Compound 21 displayed high selectivity against related inflammatory enzymes like COX-1, COX-2, 5-LOX, and FLAP.

Conclusions:

• The developed 2-phenylbenzothiazole derivatives are effective inhibitors of human mPGES-1.
• Compound 21 represents a promising lead compound for developing safer and more effective anti-inflammatory agents.
• This study provides a novel chemical scaffold for future drug discovery in inflammation.